Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.

Alum Compounds Animals Antibodies, Neutralizing Antibodies, Viral COVID-19 / prevention & control COVID-19 Vaccines Humans Immunization, Passive Mice Recombinant Proteins SARS-CoV-2 Spike Glycoprotein, Coronavirus COVID-19 Serotherapy

COVID-19 Corbevax Subunit vaccine TLR9 adjuvant Virus neutralization

Journal

Vaccine

ISSN: 1873-2518

Titre abrégé: Vaccine

Pays: Netherlands

ID NLM: 8406899

Informations de publication

Date de publication:
09 06 2022

Historique:

received: 07 07 2021

revised: 18 03 2022

accepted: 03 05 2022

pubmed: 15 5 2022

medline: 7 6 2022

entrez: 14 5 2022

Statut: ppublish

Résumé

We conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the Corbevax

Identifiants

DOI: 10.1016/j.vaccine.2022.05.007 PMID: 35568591 PMC: PMC9080055

pubmed: 35568591

pii: S0264-410X(22)00577-1

doi: 10.1016/j.vaccine.2022.05.007

pmc: PMC9080055

pii:

doi:

Substances chimiques

Alum Compounds 0

Antibodies, Neutralizing 0

Antibodies, Viral 0

COVID-19 Vaccines 0

Recombinant Proteins 0

Spike Glycoprotein, Coronavirus 0

spike protein, SARS-CoV-2 0

aluminum sulfate 34S289N54E

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

Pagination

3655-3663

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Biochim Biophys Acta Gen Subj. 2021 Jun;1865(6):129893

pubmed: 33731300

NPJ Vaccines. 2021 Oct 28;6(1):129

pubmed: 34711815

J Virol. 1995 Nov;69(11):6705-11

pubmed: 7474080

Nature. 2021 Jun;594(7862):253-258

pubmed: 33873199

Protein Expr Purif. 2022 Feb;190:106003

pubmed: 34688919

EBioMedicine. 2022 Mar;77:103902

pubmed: 35228013

Lancet. 2021 Feb 20;397(10275):682-694

pubmed: 33524311

Nat Biotechnol. 1997 Sep;15(9):871-5

pubmed: 9306402

Front Immunol. 2017 Feb 03;8:47

pubmed: 28220116

Hum Vaccin Immunother. 2021 Aug 3;17(8):2356-2366

pubmed: 33847226

Sci Transl Med. 2022 Feb 16;14(632):eabi5735

pubmed: 34914540

Vaccine. 2018 Mar 27;36(14):1853-1862

pubmed: 29496347

Science. 2021 Feb 12;371(6530):735-741

pubmed: 33436524

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4165-75

pubmed: 15217954

JAMA. 2021 Jun 15;325(23):2337-2338

pubmed: 34047758

Cell Rep. 2021 Dec 21;37(12):110143

pubmed: 34919799

Hum Vaccin Immunother. 2019;15(10):2235-2242

pubmed: 31180271

Methods Mol Biol. 2021;2197:51-85

pubmed: 32827132

Lancet. 2021 Apr 10;397(10282):1347-1348

pubmed: 33770519

Nat Microbiol. 2020 Apr;5(4):562-569

pubmed: 32094589

Vaccine. 2020 Nov 3;38(47):7533-7541

pubmed: 33039209

J Immunol Methods. 2017 Jan;440:74-82

pubmed: 27840065

Lancet Infect Dis. 2020 May;20(5):533-534

pubmed: 32087114

Appl Microbiol Biotechnol. 2021 May;105(10):4153-4165

pubmed: 33959781

Adv Drug Deliv Rev. 2021 Mar;170:71-82

pubmed: 33421475

Nat Commun. 2021 Jan 22;12(1):542

pubmed: 33483491

Vaccine. 2014 Nov 12;32(48):6377-89

pubmed: 24975812

JAMA. 2021 Apr 6;325(13):1261-1262

pubmed: 33571363

Annu Rev Med. 2016;67:405-17

pubmed: 26356803

Science. 2021 Mar 25;:

pubmed: 33766944

Nature. 2021 Jul;595(7867):426-431

pubmed: 34126625